The European Commission has approved Roche’s Tecentriq (atezolizumab) in combination with Abraxane (nab-paclitaxel) for patients with metastatic triple-negative breast cancer.

The approval was based on the results from a phase 3 clinical trial that showed a statistically significant benefit for Tecentriq in combination with nab-paclitaxel and showed that Tecentriq plus nab-paclitaxel significantly reduced the risk of disease worsening or death compared with nab-paclitaxel alone.

Tecentriq was approved by the FDA in March for use in combination with carboplatin and etoposide as a first-line treatment for adult patients with extensive-stage small cell lung cancer.